Evidence map›Paper›PMID 31624595›Full record

ArticleClinical case reports2019

High-dose-rate interstitial brachytherapy for a bulky sebaceous carcinoma of the eyelid: A case report.

Yoshiaki Takagawa, Naoya Murakami, Shigenobu Suzuki, Fumihiko Matsumoto, Seiichi Yoshimoto, Jun Itami

Abstract readCase Reports
In one paragraph

Article in Clinical case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yoshiaki TakagawaDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.ORCID https://orcid.org/0000-0001-9227-1366
Naoya MurakamiDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.ORCID https://orcid.org/0000-0003-0660-9987
Shigenobu SuzukiDepartment of Ophthalmologic Oncology National Cancer Center Hospital Tokyo Japan.
Fumihiko MatsumotoDepartment of Head and Neck Surgery National Cancer Center Hospital Tokyo Japan.
Seiichi YoshimotoDepartment of Head and Neck Surgery National Cancer Center Hospital Tokyo Japan.
Jun ItamiDepartment of Radiation Oncology National Cancer Center Hospital Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose-rate interstitial brachytherapy (HDR-ISBT) achieved excellent local control of the bulky sebaceous carcinoma of the eyelid. However, we must pay attention to dose of eyelid and cornea about late toxicity of HDR-ISBT.

Indexed as

eyelidhigh‐dose‐ratehigh‐dose‐rate interstitial brachytherapysebaceous carcinomatoxicity

Identifiers

PMID31624595
PMCPMC6787852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.